Fusion Pharmaceuticals Executives
FUSNDelisted Stock | USD 3.75 0.33 8.09% |
Fusion Pharmaceuticals employs about 101 people. The company is managed by 12 executives with a total tenure of roughly 236 years, averaging almost 19.0 years of service per executive, having 8.42 employees per reported executive. Analysis of Fusion Pharmaceuticals' management performance can provide insight into the firm performance.
Fusion |
Fusion Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2334) % which means that it has lost $0.2334 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4711) %, meaning that it created substantial loss on money invested by shareholders. Fusion Pharmaceuticals' management efficiency ratios could be used to measure how well Fusion Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Fusion Pharmaceuticals Workforce Comparison
Fusion Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,132. Fusion Pharmaceuticals holds roughly 101 in number of employees claiming about 5% of equities under Health Care industry.
Fusion Pharmaceuticals Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fusion Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fusion Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Fusion Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Christopher Leamon over six months ago Acquisition by Christopher Leamon of 106100 shares of Fusion PharmaceuticalsI at 8.44 subject to Rule 16b-3 | ||
Mohit Rawat over six months ago Acquisition by Mohit Rawat of 12843 shares of Fusion PharmaceuticalsI subject to Rule 16b-3 | ||
Meek David D over a year ago Acquisition by Meek David D of 34000 shares of Fusion PharmaceuticalsI subject to Rule 16b-3 | ||
Khuong Chau Quang over a year ago Acquisition by Khuong Chau Quang of 17000 shares of Fusion PharmaceuticalsI subject to Rule 16b-3 |
Fusion Pharmaceuticals Notable Stakeholders
A Fusion Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Fusion Pharmaceuticals often face trade-offs trying to please all of them. Fusion Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Fusion Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mohit Rawat | President Officer | Profile | |
Christopher Leamon | Chief Officer | Profile | |
John Valliant | CEO Founder | Profile | |
Eric Hoffman | Senior Development | Profile | |
Dmitri MD | Chief Officer | Profile | |
Maria Stahl | Chief Officer | Profile | |
Victor Paulus | VP Affairs | Profile | |
Cara Ferreira | Chief Staff | Profile | |
Joanne Schindler | Executive Development | Profile | |
Eric Burak | Chief Officer | Profile | |
John CPA | Chief Officer | Profile | |
Amanda Cray | Senior Communications | Profile |
About Fusion Pharmaceuticals Management Performance
The success or failure of an entity such as Fusion Pharmaceuticals often depends on how effective the management is. Fusion Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Fusion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Fusion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada. Fusion Pharmaceuticals is traded on NASDAQ Exchange in the United States.
Fusion Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Fusion Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Fusion Pharmaceuticals within its industry.Fusion Pharmaceuticals Manpower Efficiency
Return on Fusion Pharmaceuticals Manpower
Revenue Per Employee | 20.5K | |
Revenue Per Executive | 172.3K | |
Net Loss Per Employee | 939.6K | |
Net Loss Per Executive | 7.9M | |
Working Capital Per Employee | 2.2M | |
Working Capital Per Executive | 18.9M |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Fusion Stock
If you are still planning to invest in Fusion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Fusion Pharmaceuticals' history and understand the potential risks before investing.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |